Prevention of intestinal allergy in mice by rflaA:Ova is associated with enforced antigen processing and TLR5-dependent IL-10 secretion by mDC by Schülke, Stefan et al.
Prevention of Intestinal Allergy in Mice by rflaA:Ova Is
Associated with Enforced Antigen Processing and TLR5-
Dependent IL-10 Secretion by mDC
Stefan Schu¨lke1*, Sonja Wolfheimer1, Gabriele Gadermaier2, Andrea Wangorsch1,
Susanne Siebeneicher3, Peter Briza2, Ingo Spreitzer4, Dirk Schiller1, Bettina Loeschner4,
Satoshi Uematsu5, Bernard Ryffel6, Shizuo Akira5, Zoe Waibler7, Stefan Vieths1, Masako Toda3,
Stephan Scheurer1
1Division of Allergology, Paul-Ehrlich-Institut, Langen, Hessen, Germany, 2Christian Doppler Laboratory for Allergy Diagnosis and Therapy, Department of Molecular
Biology, University of Salzburg, Salzburg, Austria, 3 Junior Research Group ‘‘Experimental Allergy Models’’, Paul-Ehrlich-Institut, Langen, Hessen, Germany, 4Division of
Microbiology, Paul-Ehrlich-Institut, Langen, Hessen, Germany, 5Department of Host Defense, Research Institute for Microbial Diseases, Osaka University, Osaka, Osaka
Prefecture, Japan, 6CNRS Department of Molecular and Experimental Immunology and Neurogenetics, Allergy and Lung Inflammation, University of Orle´ans, Orle´ans,
Loiret de´partement, France, 7 Junior Research Group ‘‘Novel vaccination strategies and early immune responses’’, Paul-Ehrlich-Institut, Langen, Hessen, Germany
Abstract
Conjugated vaccines consisting of flagellin and antigen activate TLR5 and induce strong innate and adaptive immune
responses. Objective of the present study was to gain further insight into the mechanisms by which flagellin fusion proteins
mediate their immune modulating effects. In a mouse model of Ova-induced intestinal allergy a fusion protein of flagellin
and Ova (rflaA:Ova) was used for intranasal and intraperitoneal vaccination. Aggregation status of flaA, Ova and flaA:Ova
were compared by light scattering, uptake of fluorescence labeled proteins into mDC was analyzed, processing was
investigated by microsomal digestion experiments. Mechanism of DC-activation was investigated using proteasome and
inflammasome inhibitors. Immune responses of wildtype, IL-102/2, TLR52/2 mDCs and Ova-transgenic T cells were
investigated. Mucosal and i.p.-application of rflaA:Ova were able to prevent allergic sensitization, suppress disease-related
symptoms, prevent body weight loss and reduction in food uptake. Intranasal vaccination resulted in strongest suppression
of Ova-specific IgE production. These protective effects were associated with increased aggregation of rflaA:Ova and
accompanied by tenfold higher uptake rates into mDC compared to the mixture of both proteins. Microsomal digestion
showed that stimulation with rflaA:Ova resulted in faster degradation and the generation of different peptides compared to
rOva. rflaA:Ova-mediated activation of mDC could be suppressed in a dose-dependent manner by the application of both
inflammasome and proteasome inhibitors. Using TLR52/2mDC the rflaA:Ova induced IL-10 secretion was shown to be TLR5
dependent. In co-cultures of IL-102/2 mDC with DO11.10 T cells the lack of rflaA:Ova-mediated IL-10 secretion resulted in
enhanced levels of both TH2 (IL-4, IL-5) and TH1 (IL-2 and IFN-y) cytokines. In summary, mucosal vaccination with flaA:Ova
showed strongest preventive effect. Stimulation with rflaA:Ova results in strong immune modulation mediated by enhanced
uptake of the aggregated fusion protein, likely resulting in a different processing by DC as well as stronger TLR5 mediated
cell activation.
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Introduction
Bacterial flagellins, including flaA derived from L. monocytogenes,
were identified as the ligands for TLR5 [1,2], shown to be pro-
inflammatory at the picomolar range and have strong immune
modulatory activities [3–7]. Despite its undoubted immune
stimulatory potential, the actual profile of flagellin induced T
helper cell responses remains a matter of controversial discussion.
Previous reports using flagellin as an adjuvant showed either
inhibition of TH2 responses without inducing a TH1 response [7]
or induction of polarized TH2 responses by suppressing TH1
responses [5]. For example treatment of BALB/c mice, intrana-
sally sensitized to the chicken egg white allergen Ova, with a
mixture of V. vulnificus flagellin B and Ova significantly inhibited
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subsequent Ova-induced airway hyperreactivity, airway inflam-
mation, and TH2-cytokine production [7]. In contrast, in vivo
Salmonella flagellin C application stimulated strong TLR5 depen-
dent allergic airway responses to inhaled Ova and primed allergic
responses to natural indoor allergens present in house dust extracts
[8].
However, antigens conjugated with flagellin were shown to be
effective vaccines promoting antigen-specific TH1 responses in vivo
[9–14]. Conjugated flagellin vaccines have several advantages over
the mixture of antigen with flagellin: Covalent fusion of flagellin
and antigen is likely to result in targeted co-delivery of both
antigen and adjuvant to the same APC in the context of the
flagellin-mediated cell activation. On the contrary, the mixture of
flagellin and antigen may be taken up independently by different
cells. Furthermore, even if a single cell internalizes both proteins,
the flagellin:antigen ratios and therefore the type of immune
response induced will be different from cell to cell. In a worst case
scenario this may result in bystander activation of antigen-specific
TH2-responses by flagellin activated cells, as observed for the
flagellin induced priming of allergic responses to house dust
extracts [8].
In line with these considerations, flagellin antigen fusion
proteins were shown to significantly increase immunogenicity
and protective capacity against the target antigen [12,15–18]. In
previous studies we showed that fusion of L. monocytogenes flagellin A
(flaA) and the model allergen Ova resulted in strongly enhanced
mDC activation, mDC derived cytokine secretion, a suppression of
TH1 and TH2 cytokine secretion from Ova-specific CD4 T cells
and prevention of an allergic phenotype upon intraperitoneal
application [9]. Remarkably, the co-administration of both
components as a mixture did not result in similar effects.
Concordantly, in an independent study Bates et al. reported a
(Salmonella) flagellinC:Ova fusion protein to have a superior ability
to induce IL-2 secretion, T cell clustering, and T cell proliferation
compared to the equimolar mixture of both components [10].
Here, enhanced T cell activation was suggested to be mediated by
a combination of antigen-targeting to TLR5 expressing DC and
flagellin-induced signaling via TLR5 and MyD88 [10]. However,
the exact mechanism of flagellin fusion protein mediated DC
activation, likewise the internalization and processing by which the
flagellin component exerts its adjuvant activity, remain to be
clarified.
In the present study we showed that intranasal application of
rflaA:Ova fusion protein targeting theTLR5-expressing cells of the
mucosa was even more efficient in suppressing Ova-specific IgE
production and preventing Ova-induced intestinal allergic reac-
tions than intraperitoneal application. Furthermore, we investi-
gated whether structural features of such modular vaccines might
affect antigen internalization, processing, the induction and type of
antigen specific innate and adaptive immune responses.
Methods
Generation and Characterization of Recombinant
Flagellin, rOva, and rflaA:Ova Fusion Protein
Generation and purification, endotoxin depletion, and TLR5-
activation capacity of rflaA (X65624), rOva (NM205152), and
rflaA:Ova fusion protein were performed as previously described
[19].
Dynamic Light Scattering Analysis
Dynamic light scattering analysis was performed using a
Zetasizer Nano ZS (Malvern, Herrenberg, Germany). For light
scattering analysis 70 ml of rflaA (300 mg/ml), rflaA:Ova (690 mg/
ml) and rOva (1 mg/ml) in PBS were analyzed at room
temperature. Three individual measurements per protein were
performed and mean frequencies (as numbers [relative % in class])
of hydrodynamic radii (RH) in nm were plotted.
Mice
BALB/c and Ova-TCR transgenic DO11.10 mice (BALB/c
background, Jackson Laboratories, Bar Harbor, Maine, USA),
C57BL/6 mice (Harlan, Rossdorf, Germany), IL-102/2 mice
(BALB/c background), Ova-TCR transgenic OT-II and TLR52/
2, MyD882/2, Trif2/2, MyD882/2Trif2/2 mice (all C57BL/6
background) were bred at the animal facility of the Paul-Ehrlich-
Institut and kept under specified pathogen free conditions.
Ethics Statement
Animal work was approved by the local authority (Regierung-
spra¨sidium Darmstadt, Permit Number: F107/81) and conducted
in compliance with regulations of German animal welfare. All
efforts were made to minimize suffering.
Prophylactic Vaccination in a Mouse Model of Intestinal
Allergy
For prophylactic vaccination BALB/c mice (female, 8–12
weeks, n = 6 per group) were treated twice in a one week interval
by i.p.-injection with equimolar amounts of Ova (10 mg, Grade V,
Sigma, Steinheim, Germany) or rflaA:Ova (17 mg) in a total
volume of 200 ml sterile PBS, or PBS alone as control. For
intranasal application of the fusion protein 17 mg of rflaA:Ova
were applied 3 times every 3 days intranasally in a volume of
30 ml.
One week after the last vaccination, mice were sensitized to Ova
twice in a bi-weekly interval by i.p.-injection of 50 mg Ova (Grade
V) absorbed to 1 mg aluminum-hydroxide adjuvant (Pierce,
Solingen, Germany) in 200 ml sterile PBS (Ova/A). For induction
of intestinal allergy, two weeks after the second sensitization mice
were challenged by feeding egg white (EW) diet containing Ova
for 8 days or feeding a conventional diet (CN) free from Ova as
control (Group nomenclature: vaccinationRsensitizationRchal-
lenge) [20]. Blood samples were collected 1 week after each
sensitization by punctuating the tail vein and on the final day of
EW diet by cardiac puncture under deep ketamin/rompun
anaesthesia (Fig. 1A).
Evaluation of Clinical Symptoms
For the determination of symptom scores, individual mice were
assessed for softness of faeces (scores: 0 normal; 1 soft; 2 fluid; 3
mucus-like) and phenotype (scores: 0 normal fur; 1 slightly ruffed
fur; 2 strongly ruffed fur) on a daily basis (see [9]). Overall
symptom scores were calculated in the range from 0 to 5. Mean
symptom scores were calculated for each day and group.
Exemplary data of faeces conditions and phenotypes used to
generate the symptom score are depicted in Fig. S1. Moreover,
body weight, and food uptake were monitored daily.
Detection of Ova-specific IgG1, IgG2a and IgE Levels in
Mouse Sera
For determination of Ova-specific IgG1, IgG2a, and IgE
antibody titers in mouse sera, ELISA plates (Greiner Bio-One,
Solingen-Wald, Germany) were coated with 5 mg/well Ova (Ova
Grade V, Sigma,) in coating buffer (50 mM NaCO3, pH 9.6) over
night at 4uC. Serum samples (50 ml each) were diluted by serial
dilution (for IgE: 161:10, then 661:5, for IgG1 and IgG2a:
161:100, then 661:10) and incubated at 4uC overnight (IgE) or
IL-10 Secretion by Enforced rflaA:Ova Uptake
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for 2 h at room temperature (IgG1, IgG2a). Levels of Ova-specific
antibodies were measured using 50 ml secondary detection
antibody diluted in PBS supplemented with 10% FCS (IgE: rat
anti-mouse IgE biotin-conjugated, BD Biosciences, Heidelberg,
Germany, IgG1: goat anti-mouse IgG1c1 HRP-conjugated,
1:8000, IgG2a: rabbit anti-mouse IgG2a, 1:8000, both Invitrogen,
Darmstadt, Germany, incubation time: 1.5 h for IgG1 and IgG2a,
overnight for IgE) in combination with a streptavidin-HRP
antibody (for IgE detection, 50 ml diluted 1:2000 in PBS
supplemented with 10% FCS, BD Biosciences) applied for 30
minutes at room temperature. Visualization was performed with
100 ml/well TMB substrate solution (BD Biosciences) for up to 30
minutes. The reaction was stopped by addition of 50 ml/well 25%
sulfuric acid and analyzed using a SpectraMAX340PC (Molecular
Devices, California, USA) reading the absorbance at 450 nm.
Data were analyzed using Excel and SigmaPlot V11.0 (Systat
Software, Erkrath, Germany).
In vitro Generation of Murine Bone Marrow-derived
Dendritic Cells
Murine mDC were generated as described previously [19].
Briefly, bone marrow cells (BMCs) were isolated from femur and
tibia of BALB/c, C57BL/6, IL-102/2, MyD882/2, Trif2/2,
MyD882/2Trif2/2 and TLR52/2 mice and differentiated into
myeloid dendritic cells (mDC) using GM-CSF (R&D Systems,
Minneapolis, USA). On day 8 mDC were used for co-culture
experiments.
Preparation of CD4+ T Cells and DC:T Cell Co-cultures
Splenic CD4+ T cells were isolated from Ova-TCR transgenic
(DO11.10 and OT-II) mice using the CD4 T Cell Isolation Kit
(Miltenyi Biotec, Bergisch Gladbach, Germany). Knock out (IL-
102/2, TLR52/2, MyD882/2, Trif2/2, or MyD882/2Trif2/2)
and respective wild type mDC (3.26105 cells/ml) were co-cultured
either alone or with CD4+ T cells (8.06105 cells/ml,.95% purity)
and stimulated with rflaA:Ova (1.7 and 17 mg/ml) for 72 h.
Subsequently, concentrations of IL-2 (after 24 h), and IL-4, IL-5,
IL-6, IL-10, and IFN-c (after 72 h) in the supernatants were
measured by ELISA.
Antigen Uptake Assays
Recombinant proteins were labeled using the Alexa Flour 488
Microscale Protein Labeling Kit (Invitrogen) according to the
manufacturers recommendations. Comparable degrees of fluores-
cence staining were adjusted by determining the protein concen-
tration by absorbance at 280 nm and 494 nm using a Nanodrop
ND-1000 (Nano-Drop Technologies, Rockland, Delaware, USA)
according to the manufacturers recommendations and calculating
the degree of labeling with the following formula: DOL= (A4946
dilution factor)/(710006 protein conc. [M]). Protein concentra-
tions after Alexa Flour 488 labeling were confirmed using BCA
Figure 1. Intranasal and intraperitoneal vaccination with rflaA:Ova prevent Ova-induced intestinal allergy. Control (PBSRPBSRNF),
Ova-sensitized but unvaccinated animals (PBSROva/AREW), Ova-vaccinated (OvaROva/AREW) and rflaA:Ova-vaccinated (flaA:OvaROva/AREW)
animals were continuously challenged with Ova-containing pellets (EW) for 8 days (A). Mean symptom scores (B), body weight normalized to the
individual body weight before challenge (C), and mean EW-pellet uptake per mouse and day (D), were analyzed (n = 6 mice per group). NF: normal
food.
doi:10.1371/journal.pone.0087822.g001
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(Micro BCA Protein Assay Kit, Pierce, Rockford, Illinois, USA).
Subsequently, 56105 BALB/c mDC/ml were stimulated with
equimolar amounts of the labeled proteins (rOva, rflaA, rflaA+
rOva and rflaA:Ova) for 15 minutes at 37uC, extensively washed
with FACS buffer (PBS, 1% BSA, 0.3% sodium azide, 24 mM
EDTA, pH 8.0). Unspecific binding was blocked by incubation of
the cells with FC-Block (eBiosciences, Frankfurt, Germany) for 30
minutes, and then analyzed for protein uptake in
CD11c+CD11b+B220+ mDC by FACS.
Microsomal Digestion
For simulation of intracellular processing equimolar amounts of
rOva and rflaA:Ova were incubated with microsomes isolated
from bone marrow derived BALB/c mDC for 1 to 48 h [21,22].
Protein digestion was monitored by SDS-PAGE (equimolar to
2.5 mg rOva per time point and lane) and Coomassie staining.
Peptides derived from microsomal digestion were analyzed by
mass spectrometry [21,22] and obtained peptide sequences plotted
against the respective full length sequences.
Inhibition of Inflammasome and Proteasome Activation
To investigate the contribution of inflammasome and protea-
some activation to the rflaA:Ova mediated mDC activation
BALB/c mDC (3.26105 cells/ml) were preincubated for 2 h with
the different inhibitors and subsequently stimulated with either
rflaA:Ova (4 mg/ml) or LPS (10 mg/ml) for additional 22 h. For
inhibition of inflammasome activation Z-VAD and glyburide were
used, for inhibition of proteasomal degradation lactacystin was
applied according to the manufacturers recommendations (all
Sigma). Endosomal acidification was inhibited by addition of
chloroquine (Sigma).
Monocyte Activation Test
Monocyte activation tests (MAT) were performed as described
[23,24]. Briefly, 5 ml of freshly drawn blood from healthy
volunteers were stimulated with the indicated equimolar protein
amounts for 24 h in a total volume of 260 ml RPMI.
Cytokine ELISAs
The early T cell cytokine IL-2 was determined after 24 h of
stimulation, whereas IL-4 and IFN-y, secreted later after T cell
stimulation as well as IL-6 and IL-10, were determined 72 h post
stimulation. All murine cytokines were quantified using the BD
OptEIATM ELISA Sets (BD Biosciences). Cytokine levels (IL-1ß
and IL-6) in supernatants from human MAT were determined
using R&D Duo sets (R&D Systems, Wiesbaden, Germany).
Statistical Analysis
Comparison between different treatment groups was per-
formed by means of a mixed linear model with fixed factor
treatment group and random factor assay (up to 3 assays with each
two replicates). Confidence intervals for the estimated differenc-
es between treatment groups as well as p-values were either
adjusted using the Wilcoxon signed-rank test (only for compar-
ison of symptom scores), t-test (for comparison of antibody
titers) or the Bonferroni method (all other tests) in order to
restrict the overall type I error a (false positive results, i.e., false
significant differences) to 5%. P-values ,0.05, ,0.01, and ,
0.001 were designated with *, **, and *** respectively. The
statistical analyses were performed with SASH/STAT software,
version 9.2, SAS System for Windows.
Results
Intranasal Application of rflaA:Ova Prevents Allergic
Sensitization in a Murine Model of Ova-induced Intestinal
Allergy
The efficacy of intranasal flaA:Ova application to prevent
allergic sensitization was compared to intraperitoneal administra-
tion using a mouse model of Ova-induced intestinal allergy
(Fig. 1A, [20]). Both, intraperitoneal and intranasal vaccination
with the fusion protein, but not i.p. vaccination with Ova alone,
were able to prevent allergic sensitization characterized by
significantly reduced symptom scores (Fig. 1B), prevention of
body weight loss (Fig. 1C) and unchanged food uptake (Fig. 1D).
On day 7 of EW-pellet challenge, which refers to the acute phase
of the allergic response, symptom scores for rflaA:Ova vaccinated
animals were 4.4 times lower (i.p. vaccination, mean score: 0.75)
and 6.7 fold (i.n. vaccination, mean score: 0.5), respectively, than
for the unvaccinated control group (Fig. 1B, mean score: 3.33). In
contrast, i.p. vaccination with Ova alone did not result in a
significant reduction of disease symptoms (Fig. 1B, mean score:
2.33). In line with this, severe intestinal symptoms determined as
either fluid or mucus-like faeces (see Fig. S1: faeces scores 2 and 3
respectively) in combination with body weight loss and reduced
food uptake were only observed in unvaccinated or rOva
vaccinated groups but not in rflaA:Ova vaccinated animals (either
i.n. or i.p.).
Moreover, body weight loss observed in the unvaccinated
allergic control group (Fig. 1C, 89.9% of starting weight) was
prevented in mice vaccinated with the fusion protein either i.p.
(Fig. 1C, 100.75% of starting weight) or i.n. (Fig. 1C, 101.75% of
starting weight). Body weight loss in allergic and Ova-vaccinated
mice was reflected by a reduction in Ova pellet uptake, which was
not observed in mice vaccinated with the fusion protein (i.n. or i.p.,
Fig. 1D). When analyzing the humoral immune response of the
animals, vaccination with the fusion protein applied both i.p. or
i.n. resulted in a reduced production of Ova-specific IgE
antibodies (Fig. 2A, Fig. S2). Here, i.n. application of the fusion
protein proved to be superior in suppressing IgE production to the
previously evaluated i.p. route (Fig. 2A, Fig. S2, [9]). Moreover,
i.p. as well as i.n. vaccination with the fusion protein led to a
strongly enhanced Ova-specific IgG2a antibody production which
was not observed in the respective control groups (Fig. 2B, Fig.
S2). Here, no difference between the two application routes was
observed.
rflaA:Ova Forms High Molecular Aggregates which Result
in Stronger Uptake as well as Different Processing in
mDC Derived Microsomes
To further investigate the mechanism by which flagellin
containing fusion proteins mediate their strong immune modulat-
ing properties aggregation, internalization and antigen processing
were analyzed for the flaA-conjugated fusion protein, flaA, Ova
and the mixture of both components (Fig. 3). Light scattering
analysis was applied to determine the hydrodynamic radii (RH) of
the different proteins (Fig. 3A). In line with our observation that
both rflaA and rflaA:Ova tend to form aggregates (unpublished
observation) the radii determined for rflaA and rflaA:Ova were
9.05 fold (rflaA) and 7.82 fold (rflaA:Ova) higher than for rOva
(determined mean RH: rOva: 2.09 nm, rflaA: 18.92 nm,
rflaA:Ova: 16.34 nm, Fig. 3A).
To investigate whether these differences in molecule size had an
impact on protein internalization we determined the uptake of
equimolar amounts of Alexa Flour 488 labeled proteins into
IL-10 Secretion by Enforced rflaA:Ova Uptake
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C57Bl/6 wild type and TLR52/2 mDC (Fig. 3B). All proteins
were readily taken up with overall uptake levels being slightly
higher for rflaA than for rOva (Fig. 3B). In this experimental
setting the observed uptake level for rflaA plus rOva in wt mDC
corresponded to the cumulative signal observed for both protein
administered individually (Fig. 3B). In contrast, stimulation with
the equimolar amount of rflaA:Ova resulted in an approximately
10 fold higher protein uptake compared to the equimolar mixture
of both proteins (Fig. 3B). In comparison to wt mDC the uptake
level of both rflaA and the rflaA:Ova were reduced but not
completely abrogated in TLR5-deficient mDC. As expected rOva
uptake showed no difference between wild type and TLR5-
deficient cells (Fig. 3B).
Furthermore, microsomal digestion of rOva and rflaA:Ova was
applied to simulate intraendosomal degradation and compare
subsequent generation of Ova-derived peptides between the two
proteins (Fig. 4). Analysis of the degradation products via SDS-
PAGE showed that fusion of flaA to Ova resulted in faster
degradation compared to the same protein amount of rOva alone
(Fig. 4A). Whereas for rOva distinct degradation products
(apparent molecular mass less than 45 kDa) could be detected
after 48 h of microsomal digestion (Fig. 4A), microsomal digestion
Figure 2. Prophylactic vaccination with rflaA:Ova induces IgG2a and suppresses IgE production. Sera of control (PBSRPBSRNF) and
Ova-sensitized, EW-challenged mice (Ova/AREW) were collected at the end of EW-pellet feeding (day 36) and analyzed for Ova-specific IgE (A) and
Ova-specific IgG2a (B) antibody levels by ELISA (n = 6 mice per group).
doi:10.1371/journal.pone.0087822.g002
Figure 3. rflaA:Ova forms aggregates which are efficiently internalized by mDC. Hydrodynamic radii of rOva, rflaA and rflaA:Ova were
determined via lightscattering (A). Uptake of Alexa Flour 488 labelled proteins into C57Bl/6 wt (black) and TLR52/2 (blue) CD11c+CD11b+B220- mDC
stimulated with rOva (1 mg/ml), rflaA (0.7 mg/ml), rflaA (0.7 mg/ml)+rOva (1 mg/ml) or rflaA:Ova (1.7 mg/ml) was quantified 15 min post stimulation via
flow cytometry (B).
doi:10.1371/journal.pone.0087822.g003
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of rflaA:Ova resulted in almost no detectable native protein after 3
to 6 h of microsomal treatment (Fig. 4A). Analysis of the resulting
peptides via mass spectrometry revealed two major peptides
generated from rOva (amino acids 40 to 60 and 340 to 380, the
later one corresponding to the described OT-I epitope ISQAV-
HAAHAEINEAGR, Fig. 4B). In contrast, microsomal digestion of
rflaA:Ova resulted in Ova-derived peptides that were scattered
over the whole length of the Ova part of the fusion protein. No
distinct clusters were observed for rOva derived peptides (Fig. 4B).
Remarkably, processing of flagellin showed very prominent
clusters of peptides (aa residues 209 to 236) which could be
detected as early as 1 h after starting the digestion (Fig. 4B).
rflaA:Ova Mediated Cell Activation Depends on the
Inflammasome and the Proteasome
Moreover, in line with the stronger uptake of the fusion proteins
into mDC (Fig. 3B), stimulation with equimolar amounts of the
fusion protein resulted in a strongly increased cytokine secretion
(108-fold higher IL-6, and 488-fold higher IL-10 secretion for the
4 mg/ml rflaA:Ova concentration) compared to rflaA alone or the
mixture of both components (Fig. 5A). Here, application of
chloroquine, an inhibitor of lysosomal acidification [25], which
impedes the fusion of endosomes and lysosomes and subsequent
lysosomal protein degradation [26] dose-dependently inhibited
rflaA:Ova mediated mDC activation, depicted by rflaA:Ova
induced IL-6 (Fig. 5B) and IL-10 secretion [27].
To study the involvement of either inflammasome or protea-
some in mDC activation by rflaA:Ova, mDC were preincubated
with respective inhibitors before stimulation with rflaA:Ova. Here,
the rflaA:Ova induced IL-6 secretion by mDC was suppressed in a
dose-dependent manner by the application of both inflammasome
(Z-VAD-FMK, glyburide) and proteasome (lactacystin) inhibitors
(Fig. 5B). In this experiment, no dose-dependent effect of the used
inhibitors on rflaA:Ova-induced IL-10 secretion was observed.
The Immune Modulating Properties of rflaA:Ova are
Mediated via a TLR5-dependent IL-10 Secretion
Cytokine secretion upon activation of mDC by rflaA:Ova was
analyzed in order to investigate whether the enhanced internal-
ization and the enforced degradation of the Ova fusion part [9,19]
were associated with the observed immune modulation in vivo
(Fig. 6 and 7). Upon stimulation with the fusion protein,
substantial levels of immune suppressive IL-10 and proinflamma-
tory IL-6 were detectable in supernatants of bone marrow derived
mDC from wild type (wt) mice (Fig. 6). When using TLR52/2
mDC, the rflaA:Ova induced IL-10 secretion was strongly
reduced, whereas IL-6 secretion remained unaffected (Fig. 6),
demonstrating the IL-10 secretion to be TLR5 mediated and IL-6
secretion to be TLR5 independent. In this context, a potential
contamination of the fusion protein with other non-protein
stimulants was excluded by proteinase K digestion which resulted
in strongly reduced IL-6 and IL-10 secretion compared to the
undigested control (data not shown).
To further evaluate the impact of rflaA:Ova induced, TLR5-
dependent IL-10 secretion on Ova-specific T cell responses, co-
culture experiments were performed using BALB/c wt mDC or
IL-102/2 mDC and Ova-specific DO11.10 CD4+ T cells (Fig. 7).
In line with previous results stimulation of wt mDC with rflaA:Ova
resulted in predominant IL-10 secretion, whereas no IL-10 was
detected in IL-102/2 mDC controls. These results confirm, that
most of the IL-10 secretion induced upon rflaA:Ova stimulation
was attributed to the mDC population and not to the T cells [14].
In contrast to the experimental setting using wt mDCs, the lack of
rflaA:Ova mediated IL-10 secretion resulted in strongly enhanced
levels of both TH1 (IL-2:2.65 fold higher and IFN-y: 5.2 fold
higher) and TH2 (IL-4:3.46 fold higher, IL-5:2.56 fold higher)
cytokine production upon rflaA:Ova (17 mg/ml) stimulation in IL-
102/2 mDC:DO11.10 T cell co-cultures (Fig. 7). In contrast, the
Figure 4. rflaA:Ova is differently processed in mDC-derived microsomes. Microsomes were isolated from unstimulated BALB/c mDC and
used for digestion of rOva and rflaA:Ova (A+B). Protein amounts equimolar to 5 mg rOva (5 mg rOva, 8.5 mg rflaA:Ova) were digested for each
indicated time point. Subsequently, half of the samples were analyzed by SDS-PAGE (A) and for the resulting peptide pattern by mass spectrometry
B). M=molecular weight marker, arrow indicates the MW of the digested target protein. M molecular weight marker, P protein without microsomes,
M microsomes without protein, aa# amino acid residue number.
doi:10.1371/journal.pone.0087822.g004
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rflaA:Ova induced IL-6 secretion by mDC was unaffected by IL-
10 deficiency of the APC (Fig. 7).
rflaA:Ova-induced IL-6 and IL-10 secretion from mDC are
Mediated by Different Signaling Pathways
To further investigate the mechanism of rflaA:Ova induced
cytokine secretion we differentiated mDC from either MyD88-,
Trif- or MyD88/Trif-deficient mice and compared the rflaA:Ova-
induced cytokine secretion to mDC derived from C57Bl/6 wild
type control animals (Fig. 8). Here, we observed the rflaA:Ova
induced IL-10 secretion to be abrogated in both MyD88- and
Trif-deficient cells, whereas residual IL-6 secretion was still
detectable in Trif-deficient but not in MyD88-deficient mDC
(Fig. 8). In co-culture with Ova-specific OT-II CD4 T cells, only
deletion of MyD88 was sufficient to reverse the rflaA:Ova induced
suppression of TH1 cytokine secretion (Fig. 8). Here, deficiency of
the mDC for Trif showed reduced levels of IFN-y in response to
rOva and rflaA plus rOva stimulation (Fig. 8), whereas co-cultures
incorporating MyD882/2Trif2/2 mDC did not produce IFN-y
(Fig. 8).
rflaA:Ova Induces Stronger Activation of Human
Monocytes than the Mixture of both Proteins
To test whether rflaA:Ova even mediates activation of human
antigen presenting cells monocyte activation tests were performed
using peripheral blood from healthy human donors (Fig. 9). Here,
in line with the results presented in the murine system, stimulation
of human monocytes with the fusion protein resulted in a dose-
dependent, and stronger IL-1ß and IL-6 secretion than observed
with either flaA alone or both proteins applied as a mixture (Fig. 9).
Discussion
In an experimental mouse model of Ova-induced intestinal
allergy [20] both i.p and i.n. vaccination with the fusion protein
were shown to efficiently prevent allergic sensitization. Vaccina-
tion resulted in a reduction of clinical symptoms, reduced Ova-
Figure 5. flaA:Ova mediated IL-6 secretion depends on both proteasome and inflammasome activation. BALB/c mDC were stimulated
with the indicated equimolar amounts of rflaA, rflaA+rOva and rflaA:Ova for 24 h and the resulting IL-6 and IL-10 secretion in the culture supernatants
was analyzed by ELISA (A). BALB/c mDC were incubated with either the inflammasome inhibitors Z-VAD-FMK and glyburide (or the proteasome
inhibitor lactacystin) for 2 h (B). Subsequently mDC were stimulated for 22 h with 4 mg of rflaA:Ova. Supernatants were analyzed for IL-6 secretion via
ELISA. Results are mean values of three independent experiments 6 SD.
doi:10.1371/journal.pone.0087822.g005
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specific IgE levels and a predominant induction of Ova-specific
IgG2a antibodies. Here, in line with flagellin acting as a mucosal
adjuvant [11,14,28], an intranasal application of the fusion protein
was shown to be even more efficient in suppressing allergy eliciting
IgE antibodies. Therefore, flagellin containing fusion proteins hold
great potential as mucosal vaccines for the treatment of allergic
diseases.
To further elucidate the mechanisms by which flagellin fusion
proteins induce such strong protective immune responses, we
characterized the effects of rflaA:Ova stimulation on murine
mDCs as target cells for a successful vaccination [29]. Light
scattering analysis revealed that both flaA and rflaA:Ova form
high molecular aggregates in solution. This aggregation is
probably caused by spontaneous self-assembly of flagellin, which
is known from the biosynthesis of flagella. Whereas for rflaA these
aggregates are non-covalent in nature, for rflaA:Ova aggregation
further strengthened by intermolecular cysteine bonds (between
the cysteine residues of the Ova fusion part), was observed under
non reducing conditions (unpublished observation). Moreover,
uptake experiments revealed the fusion protein to be taken up
approx. 10 times more efficiently than the equimolar mixture of
both components. Using mDC derived from TLR5-deficient
animals the uptake of flaA and rflaA:Ova but not rOva was shown
to be in part mediated by TLR5. Since protein uptake was
determined 15 minutes post stimulation we think that the observed
stronger uptake of the fusion protein is mediated by receptor
mediated uptake and at this time point not yet the result of the
induced TLR5-signalling or stimulation-induced TLR5 upregula-
tion as described in Schu¨lke et al., 2011 [9]. Based on these results
we conclude, that the enhanced uptake of the fusion protein
depends on both TLR5-facilitated receptor mediated uptake as
well as an unspecific uptake of aggregates. In line with these results
a flagellinC:EGFP fusion protein was found to be efficiently
internalized, processed, and presented by mouse APC [30].
Consequently, BALB/c mice immunized with the flagellin-
C:EGFP construct developed specific CD4 and CD8 T cell
responses against the otherwise non-immunogenic EGFP [30]. We
showed that covalent rflaA:Ova aggregation may likely influence
antigen uptake, as well as subsequent processing and presentation
by DC and therefore the immunogenicity of the fusion construct.
In line with these results stimulation with equimolar amounts of
the fusion protein in direct comparison to rflaA alone or the
mixture of both proteins was shown to result in a strongly
enhanced secretion of IL-6 and IL-10 from mDC. These results
are in accordance with both our own previous results [9,27] and
the growing evidence that flagellin containing fusion proteins have
superior immune modulating capacities over the simple mixture of
both components shown by others [9–14]. In line with this, it has
been reported that the mixture of TLR-ligands and Ova (in
comparison to covalent fusion of both) has negligible impact on the
processing of Ova (Khan et al., 2007 JBC).
The rflaA:Ova-induced IL-6 secretion from TLR52/2 which
was unchanged compared to wt mDC as well as the still observed
stronger uptake of rflaA:Ova in TLR5-deficient mDC suggest that
internalisation of the fusion likely is mediated by both TLR5-
dependent and TLR5-independent mechanisms. In line with this,
Cuadros et al. speculated that the flagellin:EGFP fusion protein
does not only activate APC via TLR5 but also by increased
internalization of the complex and subsequent differences in
processing and presentation [30]. Consistently, it was hypothesized
that the size of (fusion) proteins influences processing by the APC,
with high molecular weight proteins being slightly more effectively
processed [30]. Concordantly, Zaborsky and coworkers showed
that Bet v 1 dimerization induced enhanced antigen uptake and
DC activation [31]. Moreover, Legge et al. reported that strong
aggregation observed for an Ig chimera carrying the encephali-
togenic proteolipid protein (PLP) 1 induced IL-10 production by
macrophages and DC, whereas the non-aggregated form failed to
induce IL-10 secretion [32]. Since aggregate sizes were compa-
rable for rflaA and rflaA:Ova but uptake levels were clearly
different we hypothesize, that other mechanisms besides the
observed aggregation contribute to the fusion proteins immune
modulating capacity. Here, it is noteworthy that the fusion
proteins uptake may be strongly facilitated by its binding to TLR5,
which was recently shown to promote flagellin uptake as
endocytotic receptor [33], whereas for non-glycosylated rOva no
corresponding receptor is described so far. In line with this, in a
previous study we found that mDC stimulation with rflaA:Ova
resulted in a strong upregulation of TLR5 whereas stimulation
with rflaA plus rOva in equimolar concentrations did not [9]. This
difference in the inducible TLR5 expression might also account
for the observed differences in protein uptake, despite the
comparable size of the protein aggregates, between rflaA and
rflaA:Ova. In line with the increased uptake of the fusion protein,
Figure 6. flaA:Ova induced IL-10 secretion from mDC is abrogated in TLR5 deficient mice. C57BL/6 and TLR52/2 mDC were stimulated
with rflaA:Ova. Levels of IL-6 and IL-10 were analyzed by ELISA after 72 h. Results are means 6 SD of two independent experiments.
doi:10.1371/journal.pone.0087822.g006
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pretreatment with chloroquine which blocks lysosomal acidifica-
tion and therefore subsequent lysosomal protein degradation
[25,26] was able to prevent fusion protein mediated cell activation.
Additionally, both inhibition of inflammasome and proteasome
activation were sufficient to abrogate rflaA:Ova mediated IL-6
secretion from mDC, suggesting the involvement of both processes
in fusion protein mediated cell activation.
Taken together these results suggest, that stimulation with
rflaA:Ova results in a stronger uptake of the fusion protein,
possibly mediated by a yet unknown receptor independent
mechanism (e.g. phagocytosis) and which is amplified by
additional TLR5-mediated endocytosis. Additionally, uptake of
Ova antigen conjugated to flagellin resulted in different processing
of the conjugated Ova as shown by microsomal digestion
Figure 7. Suppression of TH1 and TH2 cytokine secretion by flaA:OVA is mediated by IL-10. BALB/c mDC derived from wt and IL-102/2
mice were co-cultured with DO11.10 CD4+ T cells and stimulated with rflaA:Ova, respectively. Levels of IL-2 in the culture supernatants were analyzed
after 24 h, levels of IL-4, IL-5, IL-6, IL-10 and IFN-y were analyzed after 72 h. Results are means 6 SD of two independent experiments.
doi:10.1371/journal.pone.0087822.g007
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performed with microsomes isolated from unstimulated mDC.
Here, a faster degradation of rflaA:Ova in comparison to rOva
alone was observed, possibly due to enforced internalization and
different accessibility to protease cleavage sites. Taken together,
these processes may explain both the faster generation of Ova-
derived peptides and the broader spectrum of Ova-derived
Figure 8. rflaA:Ova-induced IL-6 and IL-10 secretion from mDC are mediated by different signaling pathways. C57BL/6 mDC derived
from C57BL/6 wt, MyD882/2, Trif2/2, or MyD882/2Trif2/2 mice were co-cultured with OT-II CD4+ T cells and stimulated with equimolar amounts of
rOva, rflaA, rflaA+rOva, or rflaA:Ova, respectively. Levels of IL-6, IL-10, and IFN-y in the culture supernatants were analyzed after 72 h. Results are
means 6 SD of two independent experiments. Please note that results from C57BL/6 and Myd882/2 cells were already published in Schu¨lke et al.,
2011 JACI.
doi:10.1371/journal.pone.0087822.g008
Figure 9. rflaA:Ova induces strong cytokine secretion from human monocytes. Monocyte activation test was performed using 5 ml of fresh
blood stimulated with the indicated, equimolar protein amounts for 24 h. Supernatants were analysed for IL-1ß and IL-6 cytokine secretion by ELISA.
Results are mean values 6 SD for four different donors.
doi:10.1371/journal.pone.0087822.g009
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peptides generated. In this experimental setting structural changes
of Ova, induced upon fusion to another protein, likely modulates
its processing by changing the accessibility of peptide bonds to
microsomal cathepsins. However, the specific peptides presented
by MHC class II and their role for the activation of Ova-specific T
cells in the context of rflaA:Ova mediated mDC activation remain
a matter of further studies.
In our previous study we observed suppression of both TH1 and
TH2 cytokine production from Ova-specific CD4 T cells upon co-
culture with rflaA:Ova stimulated mDC possibly attributed to the
strong IL-10 secretion from mDC [9]. Here, rflaA:Ova induced
IL-10 secretion was shown to be TLR5-dependent since TLR52/
2 mDC failed to produce IL-10 upon rflaA:Ova stimulation. In
contrast to this, the rflaA:Ova-induced secretion of IL-6 was found
to be TLR5-independent, suggesting that fusion protein induced
IL-6 and IL-10 secretion are regulated by different signaling
pathways. This assumption was strengthened using mDC from
MyD88-, Trif- and MyD88/Trif-deficient mice. We observed the
rflaA:Ova induced IL-10 secretion to be abrogated in both
MyD88- and Trif-deficient cells, whereas residual IL-6 secretion
was still detectable in Trif deficient but not in MyD88 deficient
mDC. In co-culture with Ova-specific OT-II CD4 T cells, only
deletion of MyD88 was sufficient to reverse the rflaA:Ova-induced
suppression of TH1 cytokine secretion [19]. Co-cultures incorpo-
rating MyD88/Trif double deficient mDC did not produce IFN-y,
probably due to the complete lack of mDC derived costimulatory
signals. This difference in rflaA:Ova-induced IL-6 and IL-10
signalling is supported by our finding that only rflaA:Ova-induced
IL-6 (but not IL-10) secretion was dose-dependently inhibited by
inhibitors of either inflammasome or proteasome.
To further elucidate the contribution of the enhanced IL-10
production to the immune modulation observed in our model we
used mDC derived from IL-10 deficient mice in co-culture
experiments with Ova-specific DO11.10 CD4+ T cells. Here we
could show that the rflaA:Ova induced suppression of TH1 and
TH2 cytokine production was reversed when using IL-10 deficient
mDC. These results clearly demonstrate the observed immune
modulation to be mediated by the mDC derived TLR5-dependent
IL-10 secretion upon rflaA:Ova mediated mDC activation.
Taken together the data presented in this study are able to
further explain the increased immunogenicity observed for this
and other flagellin:antigen fusion proteins in vivo [9–14]. We
observed a much stronger activation of professional antigen
presenting cells when stimulated with the fusion protein compared
to rflaA alone or the mixture of both proteins [9,27]. Here, in vitro
the rflaA:Ova-induced IL-10 secretion was the dominant cytokine
leading to a suppression of TH1 and TH2 responses. In conclusion
with this the rflaA:Ova-induced anti-inflammatory IL-10 secretion
seems to be mediated at least in part by a mechanism different
than the one observed for the inflammasome- and proteasome-
dependent, secretion of proinflammatory IL-6. Moreover, in vivo
we observed a prominent suppression of allergic sensitzation and
allergic symptoms with significantly reduced Ova-specific IgE
titers paralleled by a significant induction of potentially blocking
Ova-specific IgG2a antibodies. Therefore, we hypothesize that
vaccination with the fusion protein results in a strong, initial
activation of the innate immune response mediated by the
observed stronger uptake and the TLR5-induced cell activation.
Here, a covalent fusion of flagellin and antigen has clearly superior
immune activating properties compared to the simple mixture of
both components. The strong cell activation is subsequently
accompanied by a TLR5- and IL-10 mediated counter regulation
resulting in clinical tolerance towards the fused antigen (by the
suppression of TH1 and TH2 responses in vitro and the observed
suppression of CD4 and CD8 T cell activation in vivo [9]). The fact
that we observed a strong induction of Ova-specific IgG2a
antibodies upon vaccination with the fusion protein suggests, that
there might be other cell types and mechanisms involved in the
immune responses triggered by flagellin fusion proteins. In this
context further studies aim at identifying and characterizing the
contribution of other TLR5-positive cell types to the observed
effects (e.g. macrophages or epithelial cells).
Finally, using a human monocyte activation test we observed
that stimulation of monocytes with the fusion protein resulted in
both stronger IL-1ß and IL-6 secretion than observed with either
flaA alone or both proteins applied as a mixture. These results
provide first evidence for the transferability of the results derived
from mouse experiments to the human system. Here, the
enhanced cytokine secretion from human monocytes is likely of
antigen unspecific nature, but obviously mediated by the structural
features of the fusion protein and its (flagellin-mediated) immune
stimulating abilities. Further studies will address allergen-specific
immune responses in allergic compared to non-allergic donors.
In summary, our study further elucidated the mechanisms and
the potential of TLR5 ligand flagellin:allergen fusion proteins in
the context of allergies. We could show that aggregation of the
fusion protein is associated with a stronger uptake and more
efficient microsomal digestion than observed for rOva alone.
Moreover, stimulation with rflaA:Ova resulted in a strong
inflammasome and proteasome dependent mDC activation. In
contrast to IL-6 rflaA:Ova induced IL-10 secretion from mDC was
shown to be TLR5-dependent and to be sufficient for the
suppression of both TH1 and TH2 cytokine secretion observed
in Ova-specific CD4+ T cells in vitro. In a murine model of Ova-
induced intestinal allergy intranasal application of the fusion
protein was shown to protect even more from allergic sensitization
than the already established i.p. route. In conclusion, conjugated
proteins consisting of flaA and an allergen are promising vaccine
candidates for mucosal administration in specific immunotherapy
of allergies.
Supporting Information
Figure S1 Mouse phenotype and appearance of faeces
used to calculate symptom sores.
(TIF)
Figure S2 Prophylactic vaccination with rflaA:Ova in-
duces IgG2a and suppresses IgE production. Sera of
control (PBSRPBSRNF) and Ova-sensitized and EW-challenged
animals (Ova/AREW) were collected after immunization with
Ova on day 7 (A+C) or after the second immunization with Ova
on day 21 (B+D) and analyzed for Ova-specific IgE (A+B) and
Ova-specific IgG2a (C+D) antibody levels by ELISA (n = 6 mice
per group).
(TIF)
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